References

Consensus guideline for the management of peritoneal mesothelioma

10.1002/cncr.35868 · 2025 · External reference

Multisocietal consensus on the use of cytoreductive surgery and HIPEC for the treatment of diffuse Malignant peritoneal mesothelioma: a GRADE approach for evidence evaluation and recommendation

10.1002/jso.27947 · 2025 · External reference

First-line nivolumab plus ipilimumab in unresectable Malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

10.1016/s0140-6736(20)32714-8 · 2021 · External reference

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

10.1016/s0140-6736(23)01613-6 · 2023 · External reference

Clinical efficacy of immune checkpoint inhibitors in patients with advanced Malignant peritoneal mesothelioma

10.1001/jamanetworkopen.2021.19934 · 2021 · External reference

Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced Malignant peritoneal mesothelioma

10.1158/2159-8290.cd-21-0331 · 2021 · External reference

Major response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature

10.3389/fonc.2024.1410322 · 2024 · External reference

Real-world immunotherapy outcomes in unresectable peritoneal mesothelioma: a French experience

10.1016/j.ejca.2025.116066 · 2025 · External reference

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD-1/CTLA-4 dual blocker, in patients with advanced solid tumors

10.1186/s13045-023-01445-1 · 2023 · External reference

Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors: a phase 1/1b study

10.1016/j.xcrm.2025.102396 · 2025 · External reference

QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study

10.1038/s41392-023-01731-x · 2024 · External reference

Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics

10.1016/j.semcancer.2017.12.002 · 2018 · External reference